Transrectal Ultrasound Robot-Assisted Prostate Biopsy

Launched by JOHNS HOPKINS UNIVERSITY · Aug 15, 2016

Keywords

ClinConnect Summary

This clinical trial is studying a new way to perform prostate biopsies using a robot-assisted transrectal ultrasound (TRUS). Prostate cancer is a common illness in men, and doctors often use TRUS-guided biopsies to determine if a patient has cancer, especially if blood tests show high levels of prostate-specific antigen (PSA) or if a physical exam raises concerns. The trial aims to improve the accuracy of these biopsies, as traditional methods can sometimes miss cancer or do not sample the prostate evenly.

To participate in this trial, men must be scheduled for their first biopsy and have either a high PSA level (more than 4 ng/ml) or an abnormal rectal exam. However, those who already have a prostate cancer diagnosis, have had a previous biopsy, or cannot undergo the procedure due to medical reasons will not be eligible. Participants can expect to undergo a biopsy procedure that combines different techniques to improve the chances of detecting any significant cancer present. This trial is currently looking for volunteers, so if you or someone you know fits the criteria, it could be an opportunity to contribute to important research in prostate cancer detection.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Scheduled for an initial diagnostic biopsy
• • Elevated serum PSA (prostate specific antigen\> 4 ng/ml) and/or abnormal digital rectal exam
• Exclusion Criteria:
• • Clinical diagnosis of prostate cancer
• • Prior prostate biopsy
• • Anal stenosis that prevents TRUS probe insertion
• • Inadequate bowel prep
• • Unwilling or unable to sign the informed consent